Clinical Trial Update: Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial of sapanisertib in combination with fulvestrant in women with advanced or metastatic breast cancer after aromatase inhibitor therapy has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms

Drugs mentioned

• Fulvestrant (fulvestrant)
• Sapanisertib (sapanisertib)

Snippet

Sponsor: Calithera Biosciences, Inc | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2020-12-19